RTTNews BiotechCodex · 实盘不做把握 5/10
北京时间·🕒 发布 00:45:10·⟳ 抓取 00:45:32 +22s·⚡ 决策 08-22 00:46:59 +1m27s·66.8 天前
Alvotech与美时签署两款生物相似药授权商业化协议，最高里程碑款约1.5亿美元
对Alvotech（ALVO.US）方向偏正面：最高1.5亿美元潜在付款约相当于公司2026年收入指引6.5亿-7亿美元的21%-23%，约占近期约15亿-16亿美元市值的9%-10%，但兑现高度依赖开发和获批。
📄 原文RTTNews Biotech↗ 原文
Alvotech, Lotus Partner To Commercialize Durvalumab, Emicizumab Biosimilars
Alvotech (ALVO), a global biotechnology company specializing in biosimilar medicines, announced a strategic licensing a…
不做 Alvotech（ALVO.US）
协议方向偏利好且金额相对市值不小，但两款产品仍处早期/临床前，1.5亿美元主要是长期里程碑，ALVO盘中已涨3.86%，缺少高相似先例支持继续追多。
不做 美时化学制药（1795.TW）
长期商业化权利有价值，但短期先承担付款义务且台湾市场当前闭市，缺少可执行价格和明确短线正预期。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Alvotech公告与美时签署AVT34和AVT87授权商业化协议，披露最高约1.5亿美元潜在首付款及里程碑款。市场反应:RTTNews正文显示ALVO盘中报4.43美元、涨3.86%。
- RTTNews转述协议核心条款，并补充ALVO盘中涨幅。市场反应:ALVO盘中已同向上涨。
- 台湾媒体报道美时晚间重讯，拆分披露durvalumab签约付款400万美元、emicizumab签约付款100万美元及后续里程碑款。市场反应:台湾市场已收盘，1795.TW尚不能连续成交。
关键理由
- 对Alvotech（ALVO.US）方向偏正面：最高1.5亿美元潜在付款约相当于公司2026年收入指引6.5亿-7亿美元的21%-23%，约占近期约15亿-16亿美元市值的9%-10%，但兑现高度依赖开发和获批。
- 两款参照药2025年合计销售约119亿美元，说明终端市场空间大；但AVT34仍早期、AVT87仍临床前，短线基本面增量主要是合作背书而非确定收入。
- 对美时化学制药（1795.TW）长期是品项扩张利好，但短期先承担最高1.5亿美元付款义务，且台湾市场已闭市，不能用盘中价执行。
主要风险
- 本协议多数价值是开发、监管和商业化里程碑，不是一次性确定收入；若候选药开发或上市时间延后，短线催化会被削弱。
- ALVO.US信号时已报4.43美元、上涨3.86%，且公司两天前刚披露半年报和流动性改善，部分反弹可能来自财务更新而非本协议。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-19 · 影响 weakens
公司半年报显示H1调整后收入同比下降30.8%，近期通过股权融资和贷款补充流动性；这削弱了单一早期授权协议的短线确定性。
检索:Alvotech H1 2026 revenue cash balance FDA inspection financing August 2026 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-21 · 影响 weakens
AVT34仍处早期开发、AVT87仍处临床前开发，商业化收入和大部分里程碑兑现时间较远。
检索:AVT34 AVT87 development stage durvalumab emicizumab biosimilar Alvotech Lotus 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-21 · 影响 weakens
美时需支付最高1.5亿美元总金额，首付款合计500万美元，短线对1795.TW并非单边利好。
检索:Lotus Pharmaceutical Alvotech agreement payment milestones 150 million Taiwan August 21 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足使ALVO.US不从正面事件升级为ENTER，只给AVOID；美时化学制药（1795.TW）也因闭市和付款义务不确定而不做。
方向:未取得足够同市场、同阶段、同为早期生物相似药授权商业化协议的可量化先例，不能用先例支持追多。
涨幅量级:缺少高相似先例校准涨幅；本次只能按协议金额、开发阶段和盘中已涨幅压低交易强度。
形态:生物相似药早期授权通常存在里程碑兑现周期长、公告后先涨后回落的风险，但本轮未能形成可回测样本。
原文全文
展开原文 · 2,049 字
Alvotech (ALVO), a global biotechnology company specializing in biosimilar medicines, announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical covering two proposed biosimilars in the U.S. and selected Asian markets.
The agreement covers AVT34, a proposed biosimilar to AstraZeneca's Imfinzi (durvalumab), which is in early-stage development.
It also includes AVT87, a proposed biosimilar to Roche's Hemlibra (emicizumab), which is currently in pre-clinical development.
Under the semi-exclusive U.S. agreement, Alvotech will retain the right to commercialize both products directly alongside Lotus.
Lotus will market the products through its U.S.-based subsidiary, Alvogen.
Alvotech will remain responsible for product development and obtaining and maintaining U.S. marketing authorizations.
The company will also serve as the exclusive supplier of both products across all markets.
In Asia, Lotus will receive exclusive commercialization rights in eight markets, including South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia.
Lotus will be responsible for local regulatory submissions and commercialization in these markets.
The agreement could provide Alvotech with up to approximately $150 million in upfront and milestone payments, in addition to ongoing supply revenues.
The partnership expands Alvotech's commercial strategy while extending the potential reach of its biosimilar candidates across key U.S. and Asian markets.
Cash Position:
As of June 30, the cash balance was $142.8 million.
ALVO has traded between $50.25 and $92.00 over the past year. Currently, ALVO is trading at $4.43, up 3.86%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 15, 2026 03:28 ET Inflation and consumer spending figures were the main economic news from the U.S. this week, along with some data on the housing market. In Europe, the second quarter economic growth figures were in focus. The Australian central bank policy decision drew attention in Asia.
The agreement covers AVT34, a proposed biosimilar to AstraZeneca's Imfinzi (durvalumab), which is in early-stage development.
It also includes AVT87, a proposed biosimilar to Roche's Hemlibra (emicizumab), which is currently in pre-clinical development.
Under the semi-exclusive U.S. agreement, Alvotech will retain the right to commercialize both products directly alongside Lotus.
Lotus will market the products through its U.S.-based subsidiary, Alvogen.
Alvotech will remain responsible for product development and obtaining and maintaining U.S. marketing authorizations.
The company will also serve as the exclusive supplier of both products across all markets.
In Asia, Lotus will receive exclusive commercialization rights in eight markets, including South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia.
Lotus will be responsible for local regulatory submissions and commercialization in these markets.
The agreement could provide Alvotech with up to approximately $150 million in upfront and milestone payments, in addition to ongoing supply revenues.
The partnership expands Alvotech's commercial strategy while extending the potential reach of its biosimilar candidates across key U.S. and Asian markets.
Cash Position:
As of June 30, the cash balance was $142.8 million.
ALVO has traded between $50.25 and $92.00 over the past year. Currently, ALVO is trading at $4.43, up 3.86%.
For comments and feedback contact: editorial@rttnews.com
Business News
August 15, 2026 03:28 ET Inflation and consumer spending figures were the main economic news from the U.S. this week, along with some data on the housing market. In Europe, the second quarter economic growth figures were in focus. The Australian central bank policy decision drew attention in Asia.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。